code R01AX03 R03BB01PubChem 43232DrugBank APRD00537Chemical dataFormula C20H30NO3Mol. mass 389.457 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability ?Protein binding 0 to 9% in vitroMetabolism HepaticHalf albuterol and atrovent 2 hoursExcretion ?Therapeutic considerationsPregnancy cat.

oct-3-yl] 3-hydroxy-2-phenyl-propanoateIdentifiersCAS number 60205-81-4ATC code albuterol and atrovent R03BB01PubChem 43232DrugBank albuterol and atrovent dataFormula C20H30NO3Mol. mass 389.457 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability ?Protein binding 0 to 9% in vitroMetabolism HepaticHalf life 2 albuterol and atrovent ?Therapeutic considerationsPregnancy cat. B(US)Legal status POM(UK)Routes InhalationIpratropium (as ipratropium bromide, trade name Atrovent) is an anticholinergic drug administered by inhalation for the treatment of obstructive lung diseases. It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion. It is a quaternary amine and therefore does not diffuse into the blood, which prevents systemic side effects. Ipratropium is also combined albuterol and atrovent albuterol (salbutamol) albuterol and atrovent names Combivent and Duoneb) for the treatment of albuterol and atrovent lung diseases. It acts by blocking muscarinic receptors albuterol and atrovent the lung, inhibiting bronchoconstriction and mucus.

muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion. It is a quaternary amine and.